Your browser is no longer supported. Please, upgrade your browser.
AMGN Amgen Inc. daily Stock Chart
Amgen Inc.
IndexS&P 500 P/E16.48 EPS (ttm)12.02 Insider Own0.20% Shs Outstand650.22M Perf Week1.24%
Market Cap128.76B Forward P/E13.61 EPS next Y14.55 Insider Trans-0.35% Shs Float646.03M Perf Month-3.45%
Income8.46B PEG3.07 EPS next Q3.45 Inst Own79.90% Short Float1.59% Perf Quarter3.46%
Sales23.19B P/S5.55 EPS this Y7.30% Inst Trans0.16% Short Ratio4.06 Perf Half Y15.17%
Book/sh22.73 P/B8.71 EPS next Y3.83% ROA3.20% Target Price205.15 Perf Year8.23%
Cash/sh45.21 P/C4.38 EPS next 5Y5.38% ROE10.70% 52W Range163.31 - 210.19 Perf YTD13.87%
Dividend5.28 P/FCF18.00 EPS past 5Y14.40% ROI14.00% 52W High-5.79% Beta1.35
Dividend %2.67% Quick Ratio3.10 Sales past 5Y5.80% Gross Margin82.70% 52W Low21.25% ATR4.11
Employees20800 Current Ratio3.40 Sales Q/Q4.30% Oper. Margin44.20% RSI (14)43.58 Volatility2.32% 2.00%
OptionableYes Debt/Eq2.31 EPS Q/Q19.40% Profit Margin10.20% Rel Volume1.04 Prev Close201.80
ShortableYes LT Debt/Eq2.03 EarningsOct 30 AMC Payout134.80% Avg Volume2.52M Price198.02
Recom2.30 SMA20-2.81% SMA50-1.40% SMA2005.79% Volume2,632,876 Change-1.87%
Oct-01-18Initiated Cantor Fitzgerald Neutral $223
Apr-05-18Reiterated Barclays Equal Weight $190 → $180
Feb-12-18Reiterated Mizuho Buy $192 → $200
Jan-23-18Upgrade Argus Hold → Buy
Nov-01-17Downgrade Argus Buy → Hold
Oct-26-17Reiterated RBC Capital Mkts Sector Perform $192 → $188
Sep-28-17Reiterated Mizuho Buy $183 → $198
Sep-15-17Initiated RBC Capital Mkts Sector Perform $192
Jul-11-17Resumed Jefferies Buy
Jun-23-17Initiated Deutsche Bank Hold $172
Apr-05-17Downgrade Jefferies Buy → Hold
Mar-09-17Initiated UBS Neutral $185
Feb-01-17Upgrade BofA/Merrill Neutral → Buy
Dec-20-16Downgrade Credit Suisse Outperform → Neutral
Dec-13-16Initiated Oppenheimer Outperform
Nov-08-16Initiated Mizuho Buy $164
Aug-26-16Initiated Gabelli & Co Hold
Jun-29-16Initiated Bernstein Mkt Perform
Feb-25-16Initiated Citigroup Neutral $165
Feb-08-16Reiterated Argus Buy $202 → $185
Oct-22-18 03:38PM  Novartis (NVS) Q3 Earnings In Line, Revenues Beat Estimates Zacks
08:35AM  Is a Beat in Store for Bristol-Myers (BMY) in Q3 Earnings? Zacks
Oct-21-18 08:49AM  Better Buy: Biogen Inc. vs. Amgen Inc. Motley Fool
Oct-20-18 11:15AM  3 Dividend Stocks for Income Motley Fool
Oct-19-18 05:45PM  Amgen (AMGN) Dips More Than Broader Markets: What You Should Know Zacks
12:15PM  Biotech Sector Could Enter Bear Market Investopedia
09:30AM  AMGN or ILMN: Which Is the Better Value Stock Right Now? Zacks
08:36AM  10 S&P 500 Stocks to Buy for the Long Term Kiplinger
07:20AM  Investor Expectations to Drive Momentum within Amgen, Crown Castle International, Constellation Brands, Nice, NetEase, and The Hanover Insurance Group Discovering Underlying Factors of Influence GlobeNewswire
Oct-18-18 09:00AM  Amgen Invests £50 Million ($66 Million) In Oxford Nanopore Technologies PR Newswire
06:17AM  [$$] Amgen invests £50m in gene-reading company Oxford Nanopore Financial Times
Oct-17-18 03:23PM  Amgen Launches Humira Biosimilar in Europe
01:59PM  Exclusive: Express Scripts covers Amgen, Lilly migraine drugs, excludes Teva Reuters
01:38PM  Express Scripts covers Amgen, Lilly migraine drugs, excludes Teva Reuters
11:25AM  Stocks - Netflix Soars in Pre-market; IBM, Tilray, Canopy Growth Sink; Tesla Rises
09:40AM  Can Allergan's Key Drugs, Solid Pipeline Abate Generic Woes? Zacks
Oct-16-18 10:36PM  [$$] By Adding Patents, Drugmaker Keeps Cheaper Humira Copies Out of U.S. The Wall Street Journal
05:32PM  Amgen Rises 3%
12:08PM  4 Strong Stocks to Buy That Double As Big Takeover Targets InvestorPlace
08:52AM  The Daily Biotech Pulse: Enzo's Q4 Loss, Sanofi's Positive Trial Results, ImmunoCellular To Delist Benzinga
08:28AM  Amgen, Novartis kick off fight for AbbVie blockbuster drug in EU Reuters
07:00AM  [$$] Biosimilar Humira Goes on Sale in Europe, Widening Gap With U.S. The Wall Street Journal
12:00AM  Amgen Launches AMGEVITA (Biosimilar Adalimumab) In Markets Across Europe PR Newswire
Oct-15-18 09:56AM  Immune Design to Halt Cancer Vaccine Program, Shares Plunge Zacks
06:54AM  Top Ranked Income Stocks to Buy for October 15th Zacks
Oct-12-18 09:23AM  AbbVie Settles With Novartis to Delay Humira Biosimilar in US Zacks
Oct-11-18 06:01PM  Abbvie settles Humira patent disputes with Novartis unit Reuters
03:02PM  Here's Why Coherus BioSciences Fell 18.1% in September Motley Fool
01:41PM  Here's Why bluebird bio Dropped 13.3% in September Motley Fool
Oct-10-18 09:57AM  Tilary Buys Alef Biotechnology to Build Base in Latin America Zacks
Oct-09-18 04:19PM  FDA Sets Action Date for Recro's Pain Management Candidate Zacks
03:12PM  10 S&P 500 Stocks to Buy for the Long Term InvestorPlace
10:21AM  Bausch's Bryhali Gets Tentative FDA Nod for Plaque Psoriasis Zacks
Oct-08-18 08:01AM  Is Arrowhead Pharmaceuticals, Inc. a Buy on the Dip? Motley Fool
Oct-05-18 06:49PM  Cramer's lightning round: Watch outmomentum stocks are out of favor right now CNBC
Oct-04-18 06:22PM  Amgen: Compelling Valuation
03:20AM  Moody's: Biosimilars a growing challenge biotech drugs, with European market developing more quickly than the US Moody's
Oct-03-18 11:59AM  Amgen Gets FDA Nod for Once-Weekly Regimen of Kyprolis Combo Zacks
10:54AM  Biotech Stock Roundup: ALXN on Acquisition Spree, FDA Nod for REGN, AMGN Drugs Zacks
03:18AM  At a glance: Women on the boards of California companies Associated Press
Oct-02-18 02:25PM  10 Stocks to Buy When the Yield Curve Inverts InvestorPlace
10:38AM  Top Stock Reports for Chevron, Amgen & Thermo Fisher Zacks
Oct-01-18 09:30AM  Is Amgen (AMGN) Stock Outpacing Its Medical Peers This Year? Zacks
09:00AM  FDA Approves KYPROLIS® (carfilzomib) Once-Weekly 70 mg/m2 In Combination With Dexamethasone (Kd70) For Patients With Relapsed Or Refractory Multiple Myeloma PR Newswire
Sep-28-18 11:45AM  5 Breakout Stocks to Buy InvestorPlace
Sep-27-18 01:01PM  Is Amgen Inc (NASDAQ:AMGN) Attractive At This PE Ratio? Simply Wall St.
Sep-26-18 10:17PM  3 Drugmakers Not Pleased With Amarin's Fish Oil Triumph Motley Fool
12:32PM  Amgen's Neulasta Has a New Competitor in Europe
Sep-25-18 08:30AM  The Daily Biotech Pulse: Syndax Lung Cancer Trial Disappoints, Gemphire To Trim Workforce, Opiant's Offering Benzinga
Sep-24-18 09:00PM  BLINCYTO® (blinatumomab) Approved In Japan For The Treatment Of Relapsed Or Refractory B-cell Acute Lymphoblastic Leukemia PR Newswire
10:10AM  Why Amgen (AMGN) is Poised to Beat Earnings Estimates Again Zacks
Sep-22-18 12:35AM  U.S. Probes Drugmakers Over Free Services The Wall Street Journal
Sep-21-18 03:23PM  U.S. Probes Drugmakers Over Free Services The Wall Street Journal
Sep-20-18 03:12PM  The 7 Best Biotech Stocks for Investors Who Hate Risk Kiplinger
09:00AM  Amgen And Los Angeles County Announce Collaboration To Support Life Science Innovation Hub - BioLA PR Newswire
Sep-19-18 11:04AM  AbbVie Faces California Insurance Department Suit for Humira Zacks
Sep-18-18 09:30AM  Does Ajovy's Approval Make Teva a Pain-Free Stock to Buy? Motley Fool
08:37AM  The Zacks Analyst Blog Highlights: UnitedHealth, Adobe, Amgen, UPS and Bayer Zacks
Sep-17-18 06:13PM  3 High-Quality Biotech Companies for 4th Quarter
04:30PM  World's Largest Alzheimer's Survey Reveals Most Adults Believe a Cure Will be Developed in Their Lifetime PR Newswire
12:13PM  Top Research Reports for UnitedHealth, Adobe & Amgen Zacks
10:55AM  Teva Shares Pop as FDA Approves Its Migraine Drug
09:30AM  Teva stock surges 7% after FDA approves migraine medication MarketWatch
08:00AM  Teva Analysts Say Migraine Drug Approval Gives Needed Relief Bloomberg
Sep-15-18 08:45AM  Is Now a Good Time to Buy Amgen? Motley Fool
Sep-14-18 10:15AM  Why bluebird and Celgene Should Worry About Amgen's Latest Clinical Victory Motley Fool
09:35AM  Is Amgen (AMGN) a Great Stock for Value Investors? Zacks
Sep-13-18 06:30AM  Why Amgen Will Likely Be a Boring Dividend Stock Over the Next Few Years Motley Fool
Sep-12-18 11:25AM  The Outlook for AstraZeneca Is Positive, But Its Too Early to Pull the Trigger InvestorPlace
Sep-11-18 04:00PM  Amgen To Present At The Bank of America Merrill Lynch Global Healthcare Conference PR Newswire
09:46AM  Merck's Keytruda Combo Gets Nod for Lung Cancer in Europe Zacks
09:38AM  3 Top Dividend Stocks to Buy Right Now Motley Fool
08:00AM  Today's Research Reports on Trending Tickers: Amgen and Endocyte ACCESSWIRE
Sep-10-18 03:46PM  Amgen Rises 3.09%
Sep-07-18 04:00PM  Amgen To Present At The Morgan Stanley Global Healthcare Conference PR Newswire
10:21AM  AstraZeneca's Asthma Drug Gets Breakthrough Therapy Status Zacks
08:58AM  Lilly, Teva, Pfizer & Others Await FDA Decisions in September Zacks
07:55AM  The Daily Biotech Pulse: Amgen-AstraZeneca, Boston Scientific Opens Wallet, Advaxis Offering Benzinga
04:55AM  AstraZeneca gets FDA breakthrough therapy label for asthma treatment Reuters
02:46AM  AstraZeneca gets FDA breakthrough therapy label for asthma treatment Reuters
02:00AM  Tezepelumab Granted Breakthrough Therapy Designation By US FDA For The Treatment Of Patients With Severe Asthma Without An Eosinophilic Phenotype PR Newswire
Sep-06-18 03:58PM  New Class of Migraine Drug Creates Four-Way Pharma Development Race Benzinga
03:40PM  SSM Health joins six other health care systems to create nonprofit drug company American City Business Journals
08:52AM  The Zacks Analyst Blog Highlights: Amgen, Puma Biotechnology, MannKind, United Therapeutics and Vertex Pharmaceuticals Zacks
03:33AM  Hospital groups launch own company to make generic drugs Associated Press
03:31AM  Hospital groups launch own company to make generic drugs Associated Press
01:02AM  Biocartis Group NV: BIOCARTIS ANNOUNCES H1 2018 RESULTS GlobeNewswire
12:00AM  Generic-Drug Venture Backed by Hospitals Taps CEO From Amgen Bloomberg
Sep-05-18 05:15PM  Looking For Growth? Take A Look At These Biotechnology Stocks Investor's Business Daily
02:45PM  [$$] Biotech Veterans Raise $320 Million for New Life Sciences Venture Fund The Wall Street Journal
09:39AM  Biotech Stock Roundup: AMGN, PBYI Get EC Nod for Their Drugs, MNKD Soars Zacks
09:00AM  Amgen And LabCentral Open Nomination Process For Lab Residency PR Newswire
Sep-02-18 06:35AM  Better Buy: Amgen Inc. vs. Gilead Sciences, Inc. Motley Fool
Aug-30-18 09:24AM  Amgen's Leukemia Drug Blincyto Gets EU Nod for Pediatric Use Zacks
Aug-29-18 09:38AM  Biotech Stock Roundup: GILD Gets EC Nod for Yescarta, AMGN Submits Kyprolis sNDA Zacks
09:35AM  Europe ready to cash in on cheap copies of AbbVie biotech drug Reuters
09:15AM  FOCUS-Europe ready to cash in on cheap copies of AbbVie biotech drug Reuters
09:00AM  European Commission Approves BLINCYTO® (blinatumomab) For Use In Pediatric Patients With Philadelphia Chromosome-Negative Relapsed Or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia PR Newswire
Aug-28-18 12:47PM  Amgen Seeks US Approval for Its KYPROLIS in a Combo for Multiple Myeloma
11:39AM  Amgen Files for Once-Weekly Regimen for Myeloma Drug Kyprolis Zacks
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine. Its products also comprise Blincyto to treat patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia; Kyprolis, a proteasome inhibitor for the treatment of multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound. The company's marketed products include Neulasta, a pegylated protein to treat cancer patients; Aranesp to treat anemia; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; EPOGEN to treat a lower-than-normal number of red blood cells; NEUPOGEN, a recombinant human granulocyte colony-stimulating factor; and IMLYGIC to treat various cancer cells. It serves pharmaceutical wholesale distributors; and physicians or their clinics, dialysis centers, hospitals, and pharmacies, as well as consumers. The company has collaborative agreements with Pfizer Inc.; UCB; Bayer HealthCare Pharmaceuticals Inc.; and The University of Texas MD Anderson Cancer Center. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
HENDERSON REBECCA MDirectorAug 10Option Exercise63.113,000189,33016,197Aug 14 08:29 PM
Harper Sean EEVP, Research & DevelopmentJul 16Sale195.711,525298,45856,082Jul 16 08:20 PM
Harper Sean EEVP, Research & DevelopmentJun 12Sale184.271,525281,01257,510Jun 12 07:07 PM
Harper Sean EEVP, Research & DevelopmentMay 14Sale174.101,525265,50359,035May 15 07:52 PM
Piacquad DavidSVP, Business DevelopmentMay 11Option Exercise54.7115,000820,65051,566May 15 07:55 PM
Harper Sean EEVP, Research & DevelopmentApr 12Sale172.681,525263,33756,788Apr 16 07:03 PM
Harper Sean EEVP, Research & DevelopmentMar 16Sale189.751,525289,36965,682Mar 19 08:52 PM
Harper Sean EEVP, Research & DevelopmentFeb 14Sale174.181,525265,62552,089Feb 15 08:57 PM
Harper Sean EEVP, Research & DevelopmentJan 16Sale185.621,525283,07154,673Jan 17 08:19 PM
Harper Sean EEVP, Research & DevelopmentDec 12Sale176.831,525269,66656,106Dec 12 08:24 PM
Harper Sean EEVP, Research & DevelopmentNov 13Sale171.581,525261,66057,631Nov 14 07:27 PM
de Carbonnel FrancoisDirectorNov 08Sale173.614,000694,42215,528Nov 08 05:39 PM